Effect of cyclin G2 on proliferative ability of prostate cancer PC-3 cell
- 196 Downloads
This study aimed to analyze the expression, clinical significance of cyclin G2 (CCNG2) in prostate carcinoma, and the biological effect in its cell line by CCNG2 overexpression. Immunohistochemistry and Western blot were used to analyze CCNG2 protein expression in 85 cases of prostate cancer and normal tissues to study the relationship between CCNG2 expression and clinical factors. CCNG2 lentiviral vector and empty vector were, respectively, transfected into prostate cancer PC-3 cell line. Reverse transcription–polymerase chain reaction (RT-PCR) and Western blot were used to detect the mRNA level and protein of CCNG2. MTT assay and cell cycle were also conducted as to the influence of the upregulated expression of CCNG2 that might be found on PC-3 cells biological effect. The level of CCNG2 protein expression was found to be significantly lower in prostate cancer tissue than normal tissues (P < 0.05). The level of CCNG2 protein expression was not correlated with age, PSA contention, and tumor size (P < 0.05), but it was correlated with lymph node metastasis, clinic stage, and Gleason score (P < 0.05). The result of biological function shown that PC-3 cell transfected CCNG2 had a lower survival fraction, more percentage of the G0/G1 phases, and lower CDK2 protein expression compared with PC-3 cell untransfected CCNG2 (P < 0.05). CCNG2 expression decreased in prostate cancer and correlated significantly with lymph node metastasis, clinic stage, and Gleason score, suggesting that CCNG2 may play important roles as a negative regulator to prostate cancer cell.
KeywordsCCNG2 Prostate cancer Prognosis Tumor metastasis
This research was supported by the Specialized Research Fund for the Doctoral Program of Higher Education of China. The study members, their families, and their friends are thanked for their continuing support.
Conflicts of interest
- 4.Bates S, Rowan S, Vousden KH. Characterization of human cyclin G1 and G2: DNA damage inducible genes. Oneogene. 1996;13:1103–9.Google Scholar
- 7.Cui XF, Liu AJ, Xu ZM. Expression of Cyclin G2 and its clinical significance in laryngeal squamous cell carcinoma. J Clin Torhinolaryngology. 2009;23:277–9.Google Scholar
- 8.Shan G, Shan SG, Zhang XB. Expression and clinical significance of cyclin G1 and cyelinG2 in transitional cell carcinoma of bladder. Chin J Histochem Cytochem. 2009;18:268–72.Google Scholar
- 10.Shi W, Yu KR, Wu GY, Zhang H. Expression of CCNG2 in gastric carcinoma and its relationship with prognosis. Chin J Cell Biol. 2011;33:994–7.Google Scholar
- 11.Song YL, Hu GH. CyclinG2: correlation with head and neck neoplasms. Int J Otolaryngology-Head Neck Surg. 2006;30:8–11.Google Scholar
- 12.Le XF, Arachehige-Don AS, Mao W, Horne MC, Bast Jr RC. Roles of human epidermal growth factor receptor 2, c-Jun NH2- terminal kinase, PhosPhoinositide 3-kinase, and P7056 kinase pathways in regulation of cyclinG2 expression in human breast cancer cells. Mol Cancer Ther. 2007;6:2843–57.PubMedCrossRefGoogle Scholar
- 14.Chen J, Yusuf L, Andersen HM, Fruman DA. FOXO transcription factors cooperate withδEF1 to activate growth suppressive genes in B-lymphocytes. J Immunol. 2006;76:2711–21.Google Scholar